CancerICD-10: C25About 64,000 new cases per year in the US; third leading cause of cancer death

Pancreatic Cancer

Also known as: Cancer of the Pancreas, Pancreatic Adenocarcinoma

Pancreatic cancer is one of the most aggressive and lethal cancers, arising primarily from the exocrine cells of the pancreas (ductal adenocarcinoma accounts for about 90% of cases). It is difficult to detect early because the pancreas is located deep in the abdomen and symptoms are often vague until the disease is advanced. It is the third leading cause of cancer death in the United States.

Last updated November 10, 2026

Understanding Pancreatic Cancer

Pancreatic cancer is a tumor of the pancreas, the gland behind the stomach that makes digestive enzymes and insulin, and in about 9 of 10 cases it is a ductal adenocarcinoma arising from the cells that line the enzyme ducts. The American Cancer Society estimates about 67,000 new diagnoses and roughly 52,000 deaths in the United States in 2025, which makes it the third leading cause of cancer death despite being only about the tenth most common cancer, and it is projected to become the second by 2030. Median age at diagnosis is about 70, men are affected slightly more than women, and Black Americans have a higher incidence than any other group. Five-year relative survival has crept up from 6 percent in the early 2000s to about 13 percent now, and it depends heavily on stage: roughly 44 percent when the tumor is still confined to the pancreas, 16 percent once it has reached nearby nodes or structures, and about 3 percent after distant spread. Only about one in five people is diagnosed while surgery is still possible.

Nearly all pancreatic adenocarcinomas start with a mutation in the KRAS gene, found in more than 90 percent of tumors, followed over years by loss of the tumor suppressors CDKN2A, TP53 and SMAD4 as microscopic duct lesions progress to invasive cancer. The tumor surrounds itself with dense, scar-like stroma that squeezes blood vessels, which is part of why chemotherapy penetrates it poorly, and it invades nerves early, which is why pain radiating to the back is common. It also disrupts both jobs of the gland. Blocked enzyme flow causes fat malabsorption, pale greasy stools and weight loss, and tumor signals make the body insulin-resistant, so a new diagnosis of diabetes after 50 precedes the cancer diagnosis in about a quarter of patients. A tumor in the head of the gland blocks the bile duct and causes painless jaundice, which is why head tumors tend to be found earlier than those in the body or tail. Untreated metastatic disease has a median survival of a few months, and cachexia, the muscle wasting driven by tumor inflammation, affects most patients.

Care follows National Comprehensive Cancer Network and ASCO guidelines, and the first decision is whether the tumor can be removed. For resectable disease, surgery followed by six months of modified FOLFIRINOX is standard: in the 493-patient PRODIGE 24 trial, median survival was 54 months with that regimen against 35 months with gemcitabine alone. Borderline tumors are usually given chemotherapy first to shrink them. For metastatic disease, FOLFIRINOX extended median survival from 6.8 to 11.1 months over gemcitabine in a 342-patient trial, gemcitabine plus nab-paclitaxel from 6.7 to 8.5 months in 861 patients. Every patient should have germline genetic testing: the 5 to 7 percent with a BRCA mutation can receive olaparib maintenance, which doubled progression-free survival in the POLO trial, and tumor sequencing identifies the rare KRAS G12C, NTRK or mismatch-repair-deficient cancers that have targeted options. Beyond the drugs, two things measurably help: prescription pancreatic enzyme replacement, which improves nutrition and is associated with longer survival in cohort studies, and early palliative care for pain, nausea and planning.

No herb, supplement, diet or juice treats pancreatic cancer. Oral curcumin at 8 g a day in a 25-patient phase 2 study produced negligible blood levels and only two transient responses; high-dose vitamin C has shown a signal only when given intravenously in small trials, not from tablets; and there is no evidence for the ketogenic, alkaline or juice-based regimens sold to people at diagnosis. What natural products can do is make treatment more bearable, or more dangerous. Ginger reduced chemotherapy nausea in a 576-patient trial, and omega-3 fats may slow weight loss in some people with cachexia. On the other side, St John's wort cuts blood levels of irinotecan, a FOLFIRINOX drug, by about 40 percent, and ginger, fish oil, turmeric and garlic all add to bleeding risk in patients who are often on blood thinners for cancer-related clots. A 2018 analysis of the US National Cancer Database found that people who chose alternative therapy instead of standard care for four common cancers were two and a half times more likely to die. Tell the oncology team everything you take.

The most common mistake is delay, at two points. Before diagnosis, unexplained weight loss, new back pain, pale stools or a new diabetes after 50, especially in someone who is thin or losing weight, is too often treated as reflux or a back problem for months; those features together warrant a CT scan with a pancreatic protocol, not a trial of antacids. After diagnosis, the mistake is spending the weeks in which the tumor is still resectable on sequential second opinions, a dietary program or a clinic abroad. Get the opinion of a high-volume pancreatic center quickly, because Whipple mortality is about 2 percent at centers doing many a year against 10 percent or more at low-volume hospitals, and ask at the first visit for germline testing, a dietitian, enzyme capsules and a palliative-care referral, since all four are underused and none means giving up. The other mistake is accepting weight loss as inevitable: much of it is treatable malabsorption, and losing muscle before chemotherapy predicts fewer completed cycles and worse survival.

At a Glance

Common symptoms
Painless jaundice (yellowing of skin and eyes), Upper abdominal pain radiating to the back, Unexplained weight loss and loss of appetite
Main treatments
Surgical resection (Whipple procedure for head of pancreas tumors; distal pancreatectomy for tail tumors), Adjuvant chemotherapy (FOLFIRINOX or gemcitabine-based regimens), Neoadjuvant chemotherapy for borderline resectable tumors
Category
Cancer · About 64,000 new cases per year in the US; third leading cause of cancer death
See a doctor if
Unexplained jaundice (yellow skin or eyes)

Symptoms

Painless jaundice (yellowing of skin and eyes)
Upper abdominal pain radiating to the back
Unexplained weight loss and loss of appetite
New-onset diabetes in individuals over 50
Dark urine and pale, greasy stools (steatorrhea)
Nausea and vomiting
Blood clots (sometimes the first sign)
Fatigue and depression

Causes

  • Acquired genetic mutations in pancreatic ductal cells (KRAS, TP53, CDKN2A, SMAD4)
  • Chronic inflammation of the pancreas (chronic pancreatitis)
  • Inherited genetic syndromes (BRCA2, Lynch syndrome, familial pancreatitis)

Risk Factors

  • Smoking (doubles the risk)
  • Chronic pancreatitis
  • Type 2 diabetes, especially new-onset in older adults
  • Obesity
  • Family history of pancreatic cancer
  • Age over 65

Diagnosis

  • CT scan with pancreatic protocol (contrast-enhanced, thin-cut)
  • Endoscopic ultrasound (EUS) with fine-needle aspiration biopsy
  • MRI/MRCP for detailed pancreatic duct imaging
  • CA 19-9 tumor marker (useful for monitoring, not screening)
  • Staging laparoscopy if surgical resection is planned

Treatment

  • Surgical resection (Whipple procedure for head of pancreas tumors; distal pancreatectomy for tail tumors)
  • Adjuvant chemotherapy (FOLFIRINOX or gemcitabine-based regimens)
  • Neoadjuvant chemotherapy for borderline resectable tumors
  • Palliative chemotherapy for advanced disease
  • Radiation therapy in selected cases
  • Supportive care (pain management, pancreatic enzyme replacement, nutritional support)

Natural remedies for pancreatic cancer: what the evidence says

Ranked by the strength of human evidence for pancreatic cancer specifically. These sit alongside medical care, not in place of it.

  1. Most people with pancreatic cancer have exocrine insufficiency from duct obstruction or surgery, and prescription pancrelipase taken with meals reduces fat malabsorption and weight loss. In a double-blind trial of 21 patients with unresectable cancer of the pancreatic head, 8 weeks of enzyme replacement produced a 1.2 percent weight gain against a 3.7 percent loss on placebo, and a UK population study found that patients prescribed enzymes survived about twice as long (median 262 versus 125 days), although that is observational and the sickest patients may simply not have been prescribed them. Guidelines recommend it after Whipple surgery and for anyone with greasy stools or weight loss.

    Studied dose
    Prescription pancrelipase 40,000 to 50,000 lipase units with each main meal and 10,000 to 25,000 with snacks, taken at the start of eating; over-the-counter enzyme blends are not standardized and are not a substitute.
    Cautions
    Prescription products are pork-derived; very high doses have rarely caused bowel scarring; some people after surgery need an acid suppressant for the enzymes to work. Doses are adjusted by the oncology dietitian, not by trial and error.
  2. Ginger

    Moderate evidence

    In a 576-patient randomized trial across cancer types, 0.5 to 1 g of ginger extract daily for six days, starting three days before chemotherapy and taken alongside standard antiemetics, reduced acute nausea compared with placebo, with the two lower doses working best. Later meta-analyses have been mixed, with benefit for nausea more consistent than for vomiting, so it is an add-on to prescribed antiemetics, not a replacement. It does nothing to the cancer.

    Studied dose
    0.5 to 1 g of standardized ginger extract daily in two divided doses, starting 3 days before each chemotherapy cycle and continuing for 3 days after, with prescribed antiemetics.
    Cautions
    Ginger has a mild antiplatelet effect, so discuss it if you take enoxaparin, apixaban or another anticoagulant for cancer-related clots, or if your platelet count is low; it can worsen reflux; stop it a week before surgery.
  3. Cachexia drives much of the weight loss in pancreatic cancer, and EPA damps the inflammatory signals behind it. In a 200-patient randomized trial of an EPA-enriched high-protein supplement (about 2 g EPA a day) versus the same supplement without EPA, weight was stable in both groups with no significant difference overall, although people who managed the full dose gained weight and lean tissue; a 2007 Cochrane review found insufficient evidence to recommend EPA for cachexia, and the European nutrition society ESPEN says it may be considered. Expect modest benefit at best, and only as part of eating more protein and calories.

    Studied dose
    About 2 g EPA daily (for example 2 to 3 g of fish oil providing 2 g EPA and 1 g DHA), ideally within a high-protein oral nutrition supplement.
    Cautions
    Avoid on the day of and the day after platinum chemotherapy (oxaliplatin is part of FOLFIRINOX) because specific fatty acids in fish oil blunted chemotherapy effect in animal studies, a precaution several cancer centers adopt. Adds to bleeding tendency with anticoagulants and can worsen loose stools.
  4. Fat malabsorption from exocrine insufficiency, and the removal of part of the gland at surgery, make deficiency of the fat-soluble vitamins A, D, E and K common in pancreatic cancer, and low vitamin D is also linked in observational studies to worse survival. No randomized trial has shown that vitamin D supplementation lengthens survival in pancreatic cancer, and a trial of the vitamin D analog paricalcitol with chemotherapy was negative, so the goal is simply to correct a documented low level for bone and muscle health during a long course of treatment.

    Studied dose
    If 25-hydroxyvitamin D is below 20 ng/mL (50 nmol/L), 1,000 to 2,000 IU vitamin D3 daily with a meal containing fat and your enzyme capsules, rechecked after 3 months; higher repletion doses only under supervision.
    Cautions
    Doses above 4,000 IU daily without monitoring can raise calcium, which is dangerous in people who are dehydrated or losing weight. Ask for a vitamin D level rather than guessing, and have A, E, K and prothrombin time checked at the same time if you have steatorrhea.

What matters day to day

  • Stop smoking, with pharmacological help if needed: smoking roughly doubles the risk of pancreatic cancer in the first place, and continuing after diagnosis is associated with more surgical complications and shorter survival.
  • Eat small, frequent meals aiming for 1.2 to 1.5 g of protein per kilogram of body weight a day, take enzyme capsules at the start of every meal and snack, and weigh yourself weekly: unintended loss of 5 percent of body weight is the threshold at which chemotherapy tolerance falls, and an oncology dietitian referral is available at most cancer centers.
  • Keep moving through treatment with the goal of 150 minutes a week of walking or similar plus two short resistance sessions: supervised exercise programs in pancreatic cancer are safe during chemotherapy and before surgery, and preserved muscle predicts more completed chemotherapy cycles.
  • Know the warning signs of a blood clot and act on them the same day: about one in five people with pancreatic cancer develops a venous clot, so new swelling or pain in one calf, sudden breathlessness or chest pain is an emergency, and many patients are prescribed a preventive anticoagulant during chemotherapy.
  • Treat the diabetes that so often accompanies the cancer as part of cancer care, not a separate problem: blood sugar swings worsen fatigue and infection risk, enzyme replacement and steroids given with chemotherapy both change insulin needs, and after a Whipple or total pancreatectomy insulin dosing usually needs re-setting.
  • Ask for palliative care at the first visit, not the last: it means a team for pain, nausea, sleep and decisions alongside active treatment, and trials in advanced cancers show it improves quality of life and mood and, in some studies, length of life.

Prevention

  • Quit smoking or never start
  • Maintain a healthy weight
  • Limit alcohol to reduce chronic pancreatitis risk
  • Genetic counseling for families with inherited pancreatic cancer syndromes

When to See a Doctor

  • Unexplained jaundice (yellow skin or eyes)
  • Persistent upper abdominal or back pain with weight loss
  • New-onset diabetes after age 50 without typical risk factors
  • Unexplained blood clots

Frequently Asked Questions

References

  1. Conroy T, Hammel P, Hebbar M, et al.. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. New England Journal of Medicine (2018)
  2. Conroy T, Desseigne F, Ychou M, et al.. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine (2011)
  3. Von Hoff DD, Ervin T, Arena FP, et al.. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine (2013)
  4. Golan T, Hammel P, Reni M, et al.. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. New England Journal of Medicine (2019)
  5. Bruno MJ, Haverkort EB, Tijssen GP, et al.. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut (1998)
  6. Fearon KC, Von Meyenfeldt MF, Moses AG, et al.. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut (2003)
  7. Ryan JL, Heckler CE, Roscoe JA, et al.. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Supportive Care in Cancer (2012)
  8. Mathijssen RH, Verweij J, de Bruijn P, et al.. Effects of St. John's wort on irinotecan metabolism. Journal of the National Cancer Institute (2002)
  9. Dhillon N, Aggarwal BB, Newman RA, et al.. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clinical Cancer Research (2008)
  10. National Cancer Institute. Pancreatic Cancer (2025)View source

Related Conditions

Have questions about Pancreatic Cancer?

Ask Mother Nature AI for personalized, evidence-based guidance.

Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.